| Acute Lymphoblastic Leukemia |
Ly294002 (PI3K inhibitor) |
WT |
Synergistic apoptosis induction |
[45] |
| Acute Myeloid Leukemia |
1,25-dihydroxyvitamin D(3) |
WT |
Enhanced apoptosis |
[90] |
| Acute Myeloid Leukemia |
AZD6244 (inhibitor of MEK signaling) |
WT |
Synergistic apoptosis induction |
[91] |
| Acute Myeloid Leukemia |
inhibition of X-linked inhibitor of apoptosis (XIAP) by antisense oligonucleotide |
WT |
Synergistic apoptosis induction |
[92] |
| Acute Myeloid Leukemia |
MK-0457 (Pan-Aurora kinase inhibitor) |
WT |
Synergistic apoptosis induction |
[93] |
| Acute Myeloid Leukemia |
PI-103 (dual PI3 kinase/mTOR inhibitor) |
WT |
Synergistic apoptosis induction |
[94] |
| Acute Myeloid Leukemia |
TRAIL (death ligand) |
WT |
Synergistic apoptosis induction |
[89] |
| Acute Myeloid Leukemia |
PD98059 (inhibitor of mitogen- activated protein kinase kinase) |
WT |
Synergistic apoptosis induction |
[95] |
| Acute Myeloid Leukemia |
ABT-737 (inhibitor of Bcl-2) |
WT |
Synergistic apoptosis induction |
[96] |
| B Lymphoid & Myeloid Leukemia |
Perifosine (alkylphospholipids) |
WT |
Synergistic Cytoxicity |
[97] |
| B-cell chronic lymphocytic leukemia cells |
Dasatinib (Multi-kinase inhibitor) |
WT & Mutant |
Synergistic Cytoxicity |
[88] |
| B-cell chronic lymphocytic leukemia cells |
Doxorubicin, Chlorambucil & fludarabin (Chemotherapy Drugs) |
WT |
Synergistic apoptosis induction |
[81] |
| Endometrial and Ovarian cancer cells |
Low-dose Mithramycin (inhibitor of Sp1 DNA binding) |
WT |
Synergistic apoptosis induction |
[98] |
| Hepatocellular carcinoma |
Doxorubicin (Chemotherapy Drug) |
WT & Mutant |
Enhanced Chemosensitivity |
[99] |
| Laryngeal Carcinoma |
Radiation |
WT |
Enhanced Radiosensitivity |
[85] |
| Lung Cancer |
Radiation |
WT |
Enhanced Radiosensitivity |
[100] |
| Malignant Peripheral Nerve Sheath & Colon Cancer cells |
Cisplatin, Carboplatin & Doxorubicin (Chemotherapy Drugs) |
Mutant & Null |
Synergistic apoptosis induction |
[71] |
| Multiple Myeloma |
RITA (inhibitor of p53-MDM2 interaction) |
WT |
Synergistic Cytoxicity |
[101] |
| Melanoma, Colon & Breast Cancer cells |
Roscovitin & DRB (CDK inhibitors) |
WT |
Synergistic apoptosis induction |
[87] |
| Mantle Cell Lymphoma |
Bortezomib (Proteasome inhibitor) |
Mutant |
Synergistic apoptosis induction |
[102] |
| Multiple Myeloma |
Velcade (Proteasome inhibitor) |
WT |
Synergistic Cytoxicity |
[103] |
| Neuroblastoma |
Doxorubicin (Chemotherapy Drug) |
Null |
Enhanced Chemosensitivity |
[76] |
| Neuroblastoma |
Cisplatin & Etoposide (Chemotherapy Drugs) |
WT |
Synergistic apoptosis induction |
[104] |
| Prostate Cancer Cells |
Radiation |
WT & Mutant |
Radio-sensitized under hypoxic conditions |
[86] |
